Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPICA: Ropivacaine via ICC for Postoperative Analgesia
NCT04939545Phase 3Completed
- Sponsor
- University Hospital Basel
- Start
- Dec 2021
- Primary completion
- Mar 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (2 arms), sponsored by University Hospital Basel. Primary endpoint: Change in Pain Numerical Rating Scale While Coughing at 72 hours. Started Dec 2021; status: completed.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04939545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939545.